The Remember Me feature is an automatic login process which creates a cookie on the hard drive of your computer containing a unique identifier which ASCO.org will utilize to remember you by, thereby avoiding the need to enter username and password upon subsequent visits to ASCO.org. DO NOT select this option if you share this computer with others since transactional, personal, or member only information will be accessible by other users.
To activate the Remember Me option, click the empty check box when signing in to the site. The Remember Me functionality is deactivated at the logout.
For additional information please review our Privacy Policy.
ALEXANDRIA, Va. - The American Society of Clinical Oncology (ASCO) today published a detailed review of the "Top Five" opportunities to improve the quality and value of cancer care by curbing use of common tests and treatments that are not supported by clinical evidence. Published in the Journal of Clinical Oncology, the new article coincides with the announcement of several Top Five lists as part of the Choosing Wisely® campaign. ASCO is one of nine specialty societies participating in the campaign, which is sponsored by the American Board of Internal Medicine (ABIM) Foundation.
ALEXANDRIA, Va. – Today the American Society of Clinical Oncology (ASCO) issued a new clinical practice guideline on the appropriate dosing of chemotherapy drugs for obese adult patients with cancer. The guideline recommends that physicians routinely use an obese patient’s actual body weight, rather than an ideal body weight or other estimate, to calculate the appropriate dose of nearly all chemotherapy drugs. The guideline was released on April 2, 2012.
ALEXANDRIA, Va. - Summary of a study being published online March 12, 2012 in the Journal of Clinical Oncology, reporting that five- and 10-year survival increased steadily among children and teenagers treated for acute lymphoblastic leukemia (the most common type of pediatric cancer) between 1990 and 2005, as part of Children's Oncology Group clinical trials. Similarly, death rates from ALL fell by 30 to 50 percent during the study period.
ALEXANDRIA, Va.-Summary of a study being published online February 27, 2012 in the Journal of Clinical Oncology, showing that women who underwent a once-common chemotherapy regimen known as CMF between 1976 and 1995 score slightly lower on cognitive tests that measure word learning, memory and information processing speed than women without a history of cancer.
ALEXANDRIA, Va.- Summary of the first prospective study – published online February 13, 2012 in the Journal of Clinical Oncology – to provide strong evidence of increased breast and pancreatic cancer risk in individuals with Lynch syndrome, who carry certain inherited genetic mutations in DNA repair genes. The study is also the first to show that relatives of people with Lynch syndrome who do not carry these mutations have no increased risk of cancer.
ALEXANDRIA, Va. - Summary of a study being published online December 12, 2011, in the Journal of Clinical Oncology finding children of childhood cancer survivors do not have an increased risk for birth defects – despite the fact that their parents received treatment with radiation and/or certain forms of chemotherapy that can damage the DNA of cancer cells and healthy cells alike. The findings provide reassurance to cancer survivors about the potential effects of their own treatment on their children, and help guide family planning.
ALEXANDRIA, Va.- Summary of a study being published online October 31, 2011, in the Journal of Clinical Oncology finding that close relatives of women who carry mutations in a BRCA gene – but who themselves do not have such genetic mutations – do not have an increased risk of developing breast cancer compared to relatives of women with breast cancer who do not have such mutations. These results run counter to a previous study showing a higher risk for these women, and suggest they may not need extra cancer screening and other preventive measures.
ALEXANDRIA, Va. - A new study of oropharyngeal cancer suggests that dramatic increases in U.S. incidence of the cancer and survival since 1984 can be attributed to infection with the human papillomavirus (HPV). Using samples collected from registries in three states, researchers showed that the proportion of oropharyngeal cancers - particularly among men - that tested positive for HPV increased significantly over time, from slightly more than 16 percent of such cancers diagnosed during the 1980s to more than 70 percent diagnosed during the 2000s.
ALEXANDRIA, Va.- The American Society of Clinical Oncology (ASCO) today issued an update to its clinical practice guideline on the use of antiemetic medications to prevent vomiting and nausea resulting from treatment with chemotherapy and/or radiation. The new guideline includes comprehensive, stratified recommendations on the use of antiemetics during treatment with chemotherapy drugs that are classified as high, moderate, minimal and low risk for causing vomiting and nausea.
ALEXANDRIA, Va. - A new study has shown that magnetic resonance imaging (MRI) used to evaluate responses to pre-surgery (neo-adjuvant) chemotherapy or radiation may predict survival among patients with advanced rectal cancer. The findings suggest that MRI-assessed tumor responses to neoadjuvant therapy can help physicians to better plan their patients' subsequent treatments.
